Development trends for new cancer therapeutics and vaccines

Global commercial development of cancer treatments has dramatically increased over the past 15 years. To assess trends in the process, we analyzed data for 1111 candidates that entered clinical study during 1990–2006. Our results show that although the average number of therapeutic candidates enteri...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2008, Vol.13 (1), p.30-37
Main Authors: Reichert, Janice M., Wenger, Julia B.
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cancer Vaccines - biosynthesis
Cancer Vaccines - pharmacology
Cancer Vaccines - therapeutic use
Drug Industry
General aspects
General pharmacology
Humans
Medical sciences
Neoplasms - drug therapy
Neoplasms - therapy
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Global commercial development of cancer treatments has dramatically increased over the past 15 years. To assess trends in the process, we analyzed data for 1111 candidates that entered clinical study during 1990–2006. Our results show that although the average number of therapeutic candidates entering clinical study per year more than doubled, the US approval success rate was low (8%) during the period. The therapeutics took seven years on average to go through the clinical and US approval phases, but cancer vaccines have yet to gain any US approvals. These results indicate that improvement in the efficiency of the development process for innovative cancer treatments is needed.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2007.09.003